Medical Excellence Capital
Venture capitalActively deployingNew York · Pre-Seed–Series B · 17 people tracked
Also known as Medical Excellence Capital Partners ll · MEDICAL EXCELLENCE CAPITAL, LLC
Investment thesis
MEC is a purpose-built venture firm investing in precision health and life sciences innovation. It backs company creation, seed, Series A, and Series B opportunities where technology and novel approaches — often leveraging artificial intelligence — are transformative for patient care and address large, unmet medical needs. The firm believes the coming decade will bring a golden age of life sciences innovation driven by AI, and it deploys 'precision capital' supported by a proprietary national medical network platform to nurture companies solving the biggest and most complex medical problems.
Source: firm website, verified Aug 3, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 14 of 19 portfolio companiesBiotech ×13Medical Devices ×10Deep Tech ×6AI & Machine Learning ×3Digital Health ×3Healthtech ×3
HQs:United States×9
Investments · 19 tracked
founders shown can be your intro pathProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).
BiotechDeep TechMedical DevicesNissequogue, US
John Prufeta(Director)Eric Heil(Director)Joni Mancini(Executive Officer)Valerie Estess(Director)
BoardBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)
Board seatEric Heil· per SEC Form D
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)
BiotechNew York, US
Andrea Spezzi(Executive Officer, Director)John Prufeta(Director)Eric Heil(Director)
Board seatEric Heil· per SEC Form D · $5M raise · filed Sep 2022
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices<UNKNOWN>, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Avilar develops protein degrader drugs targeting extracellular and membrane-bound proteins, using a novel class called ATACs that harness endolysosomal degradation machinery.
AI & Machine LearningBiotechMedical DevicesWaltham, US
THERESA CAMERON(Director)PAULINA HILL(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)
Company developing oral small-molecule CLIC1 inhibitors to treat obesity and metabolic diseases through hunger-pathway modulation.
ClicBio develops oral small-molecule CLIC1 inhibitors to treat metabolic diseases by modulating appetite through hypothalamic neuron regulation.
BiotechDeep TechHealthtech
John Dobak(CEO and Co-Founder)Jay Hagan(Board Member and Co-Founder)Bruce Steel(Board Member and Co-Founder)Olivia Osborn(Co-Founder/Advisor)
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.
AI & Machine LearningBiotechMedical DevicesCambridge, US
George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)Alex Ng(Chief Innovation Officer & Co-Founder)
Precision immunotherapy company using single-cell genomics and machine learning to develop novel cancer treatments, with lead programs in clinical development.
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Laura Brass(Director)Amanda Wagner(Executive Officer)Kai Wucherpfennig(Director)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
Biotech company developing Spiroligomer™ molecules as a new class of targeted therapeutic medicines for diagnostic and therapeutic applications.
Spinout from Children's Hospital of Philadelphia using AI and machine learning to develop therapies for genetic diseases in children.
Nobias Therapeutics develops small-molecule drug candidates for genetically-defined rare diseases, primarily in pediatric populations.
Biotech
Pleno develops an instrument platform for genomic testing that enables AI-driven precision medicine through faster, lower-cost multiomics analysis.
AI & Machine LearningBiotechMedical Devices
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform.
BiotechHealthtechSan Carlos, US
Matias Porras Paniagua(Director)Caitlyn Miller(CEO & Co-Founder)Omri Amirav-Drory(Director)John Prufeta(Director)Jennifer Cochran(Co-Founder)Carolyn Bertozzi(Co-Founder)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Medical Excellence Capital invest at?
- Medical Excellence Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does Medical Excellence Capital focus on?
- Medical Excellence Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Medical Excellence Capital located?
- Medical Excellence Capital is headquartered in New York, US.
- Does Medical Excellence Capital lead rounds?
- Medical Excellence Capital typically participates in rounds rather than leading them.
From the blog
visit blog ↗Recent posts cover advancements in regenerative medicine including iPSC-derived cell therapies for neurodegenerative diseases and nonviral gene delivery platforms for genetic disorders. AI summary
Media · Podcasts & interviews
featuring the teamAsk an Investor featuring Kim Kamdar of Medical Excellence Capital
UC San Diego Innovation · Kim Kamdar
Co-investors · 16
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Foothill Ventures is a technology-focused venture fund based in Los Altos, California, run by a team with founder and operator backgrounds. It makes early-stage investments in frontier technology, particularly infrastructure and AI applications.
.jpeg)
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OUP (Osage University Partners) is a venture capital firm that backs science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Illuminate Ventures is an early-stage venture firm focused on B2B/enterprise software companies, typically serving as a startup's first institutional investor and leading Series Seed rounds.
Johnson & Johnson Innovation is the innovation arm of Johnson & Johnson, working to advance life science innovation through early partnerships, incubation via JLABS, venture investing through JJDC, and late-stage partnerships to address global health challenges.
Morgenthaler is a venture capital and private equity firm that has focused on building valuable companies for over 40 years.
Cofounders Capital is a North Carolina-based venture firm that leads seed-stage investments in B2B software companies across the southeastern United States.
▶4 more co-investors
MPM BioImpactQuesta CapitalHealthQuest CapitalVertex Ventures HC
Firms observed investing alongside Medical Excellence Capital, from public investor directories. Shared companies are the overlap with Medical Excellence Capital's recorded portfolio.
Similar investors
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Rising Tide is a venture capital firm investing across sectors including healthcare, life sciences, AI infrastructure, space and communications, fintech, and crypto.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Seido Capital is a North American venture capital firm investing in life sciences and deep tech companies from pre-seed to IPO, building on the legacy of the Belgian Theodorus funds.
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.